Anti-inflammatory cytokine pathway (null)

Anti-inflammatory cytokine pathway Overview

The anti-inflammatory cytokine pathway is a complex network of signaling molecules and receptors that regulates the immune system to prevent excessive tissue damage (Opal & DePalo, 2000, PMC137246). Key components include cytokines such as Interleukin-10 (IL-10), Interleukin-4 (IL-4), and Transforming Growth Factor-beta (TGF-beta), which act to suppress the production of pro-inflammatory mediators like TNF-alpha and IL-1 (Iyer & Cheng, 2012, Genes & Cancer). These cytokines bind to specific receptors, such as the IL-10 receptor, triggering intracellular cascades like the JAK-STAT3 pathway to promote an anti-inflammatory gene expression profile (Saraiva & O'Garra, 2010, Nature Reviews Immunology). In many diseases, including rheumatoid arthritis and inflammatory bowel disease, this pathway is insufficient to counteract chronic inflammation (Asadullah et al., 2003, Pharmacological Reviews). Therapeutic strategies have explored the use of recombinant cytokines like Ilodecakin (rIL-10) to bolster this pathway, though clinical success has been limited by the short half-life of the proteins and systemic side effects (Tilg et al., 2002, Gut). Additionally, TGF-beta modulation is a focus in oncology and fibrotic diseases due to its dual role in immune suppression and tissue remodeling (Batlle & Massagué, 2019, Immunity).

Mechanism of Action

Modulation of the pathway involves the use of recombinant cytokines or monoclonal antibodies to either enhance anti-inflammatory signaling (e.g., IL-10 receptor activation) or neutralize cytokines that contribute to pathological inflammation or fibrosis (Opal & DePalo, 2000, PMC137246; Batlle & Massagué, 2019, Immunity).

Biological Functions

Safety Considerations

Interacting Drugs

Associated Biomarkers